Camoteskimab

DRUG3 trials

Sponsors

Apollo Therapeutics Limited, Apollo Therapeutics Ltd

Conditions

AtopicAtopic DermatitisAtopic Dermatitis (AD)DermatitisDermatitis, AtopicDermatologic DiseaseEczemaEczema Atopic Dermatitis

Phase 2

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

CompletedNCT06436183

Apollo Therapeutics LtdAtopic, Atopic Dermatitis, Dermatitis +4

Start: 2024-05-01End: 2025-08-12Updated: 2025-09-18

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT07599813

Apollo Therapeutics LtdAtopic, Atopic Dermatitis, Dermatitis +5

Start: 2026-05-28End: 2028-04-30Target: 280Updated: 2026-08-28

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

Not yet recruitingCTIS2026-525673-39-00

Apollo Therapeutics LimitedAtopic Dermatitis (AD)

Target: 31Updated: 2026-08-25